Products aP booster + TdaP booster + Licensed TdaP booster (Boostrix®)
aP booster + TdaP booster + Licensed TdaP booster (Boostrix®) Phase 1 Completed 💤 Quiet Apr 1, 2015 → Jun 1, 2015
About aP booster + TdaP booster + Licensed TdaP booster (Boostrix®) aP booster + TdaP booster + Licensed TdaP booster (Boostrix®) is a phase 1 stage product being developed by Novartis for Pertussis. The current trial status is completed. This product is registered under clinical trial identifier NCT02382913. Target conditions include Pertussis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02382913 Phase 1 Completed Apr 1, 2015 Jun 1, 2015 Pertussis
Product Company Stage Hype Score Adacel® Sanofi Approved Boostrix + Placebo (Saline) Novartis Approved Acellular pertussis vaccine + Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) + Licensed TdaP booster vaccine + Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) Novartis Phase 1 Tetanus Toxoid, acellular pertussis, diphtheria toxoid Sanofi Pre-clinical ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed Sanofi Approved COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®) Sanofi Approved (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis Sanofi Phase 1/2 DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+Hib Sanofi Phase 3 Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV + Hepatitis B vaccine Sanofi Phase 2 DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) Sanofi Phase 3 Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine Sanofi Approved Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) + Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) Sanofi Approved Pentacel® (DTaP-IPV/Hib) + Other Pertussis Vaccines Sanofi Pre-clinical DTaP-IPV combined vaccine + DTaP vaccine Sanofi Phase 3 ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed Sanofi Approved Tetanus and diphtheria toxoids and acellular pertussis Sanofi Pre-clinical
Other Products from Novartis